Max Delbrück Center MDC - Max-Delbrück-Centrum für molekulare Medizin in der Helmholtz-Gemeinschaft

Our Research

Research at the Max Delbrück Center aims to elucidate the molecular mechanisms of health and disease, and translate those findings into medical practice.

Scientific image

Our newsletter

Stay connected and find out more about our research, innovations and campus life! Subscribe now to our monthly newsletter Insights.

More details

Further information
LNdW2016_Anyess_072_Labtours

Research Highlights

Our research teams publish around 450 specialist articles every year. Our research highlights can be found here, presented in a comprehensible format.

More information

Selection of research highlights
induced pluripotent stem cells in a pluripotency test

Research News & Events

Symbolbild Highly Cited Researchers

Global influencers of science

Three researchers at Max Delbrück Center – Sofia Forslund, Friedemann Paul, and Nikolaus Rajewsky – are among the most Highly Cited Researchers in the world in 2024, making the list two years in a row. Germany ranks fourth of countries and regions, behind the U.S., mainland China and the U.K.
woman with a scientific chip
Science

The innovator

As Scientific Director of Max Delbrück Center, Maike Sander is driving a bold shift toward interdisciplinary research to address the health challenges of our time. As a diabetes researcher, her next frontier is to use organ-on-a-chip technologies to build more accurate models of the human pancreas.
2D map of gene expression in the metastatic lymph node
Science

Beyond ChatGPT: Foundation models for research

Foundation models are complex AI applications with enormous potential. Trained on vast datasets from medicine, climate, or material science, they can uncover new relationships and make predictions. Helmholtz is supporting this pioneering work, with €5.55 million going to the Max Delbrück Center.
woman
Science

From research to application

The Max Delbrück Center proudly welcomes Dr. Nevine Shalaby as the new Head of the Innovation and Entrepreneurship Department. With a rich background in genetics and industry, she aims to drive research impact, foster spin-offs, and strengthen industry partnerships, aligned with the Strategy 2030.
Scientific image

Cancer risk linked to p53 in Ulcerative Colitis

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated the role of the p53 gene in ulcerative colitis. The study, published in “Science Advances,” suggests a potential new drug target to stop disease progression to cancer.
SPARK Discoverers Visual

A dialogue between science and art

From November 1 to 10, 2024, researchers and science enthusiasts will come together during Berlin Science Week to discuss important questions about science and society. Kicking off the week, the Max Delbrück Center will present its photo exhibition “Discoverers” for the first time.
Kras-Driven Lung Cancer
Science

Navigating cancer treatment with the help of AI

Cancer treatment has become complex. An AI based online tool developed by researchers at the Max Delbrück Center can already help oncologists and cancer patients find the most up to date personalized treatment.
Summit 24- Maike Sander

Perspectives for the medicine of the future

What opportunities lie ahead for the future of medical research and healthcare? Scientists from the Helmholtz Association share their ideas with decision-makers from science, politics, patient organizations, biotech, and the pharmaceutical industry at the first Helmholtz Health Summit in Berlin.
Porträt Maike Sander MDC
Science

Medicine needs more innovation

We at the Helmholtz Association have everything we need to leverage the potential of biomedical engineering in Germany. We simply need to assemble all the puzzle pieces thoughtfully and unite people who have never collaborated before, says our Scientific Director Maike Sander.

All News & Events

Publications

Concurrent profiling of localized transcriptome and RNA dynamics in neurons by spatial SLAMseq

Methods Mol Biol

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology

Leuk Res

Generation of two isogenic human iPSC lines (ZIPi013-B-1, ZIPi013-B-2) carrying a CRISPR/Cas9-mediated deletion of TRPM4

Stem Cell Res

From regulation of cell fate decisions towards patient-specific treatments, insights from mechanistic models of signalling pathways

Curr Opin Syst Biol

All Publications